Deep Longevity is developing explainable artificial intelligence systems to track the rate of aging at the molecular, cellular, tissue, organ, system, physiological, and psychological levels. It is also developing systems for the emerging field of longevity medicine that'll enable physicians to make better decisions on the interventions that may slow down, or reverse the aging processes. Deep Longevity has developed a Longevity as a Service (LaaS)© solution to integrate multiple, deep biomarkers of aging dubbed “deep aging clocks” to provide a universal multifactorial measure of human biological age. Deep Longevity started its journey in 2020 after securing a round of funding from the most credible venture capitalists specializing in biotechnology, longevity, and artificial intelligence. ETP Ventures, Human Longevity and Performance Impact Venture Fund, BOLD Capital Partners, Longevity Vision Fund, LongeVC, co-founder of Oculus, Michael Antonov, and other expert AI and biotechnology investors supported the company.